Ovarian Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Ovarian Cancer Diagnostics Market is projected to expand from USD 2.21 Billion in 2025 to USD 3.02 Billion by 2031, registering a compound annual growth rate of 5.34%. This sector comprises laboratory assays and medical procedures aimed at identifying malignant neoplasms in the ovaries, fallopian tubes, and peritoneum through methods such as genetic screening, tumor biomarker testing, and transvaginal ultrasound. A primary catalyst for this growth is the rising global incidence of gynecological cancers alongside the increasing uptake of genetic testing for BRCA mutations in high-risk groups. As reported by the American Cancer Society, an estimated 20,890 women in the United States will be diagnosed with ovarian cancer in 2025, highlighting the urgent need for precise diagnostic solutions to enable timely treatment and enhance patient outcomes.

Despite these positive indicators, the market confronts substantial hurdles arising from the expensive nature of genomic testing and the lack of a standardized, sensitive screening protocol for early-stage detection in the general public. Because the disease is frequently identified only after reaching advanced stages, the effectiveness of existing therapeutic options is reduced, which effectively prevents the widespread adoption of routine diagnostic screening initiatives. Consequently, these challenges limit the implementation of mass screening programs, thereby constraining the market's potential reach beyond symptomatic or high-risk populations.

Market Drivers

The primary engine propelling market growth is the rapid advancement of diagnostic imaging and biomarker analysis technologies, specifically the rise of artificial intelligence (AI) and non-invasive liquid biopsy. These innovations utilize multi-omic platforms to enhance sensitivity in detecting early-stage malignancies, effectively addressing the shortcomings of conventional CA-125 testing. Furthermore, machine learning algorithms facilitate the accurate detection of tumor-derived extracellular vesicles and circulating gangliosides, minimizing false positives that have historically impeded screening success. For instance, data presented by AOA Dx at the 2025 AACR Annual Meeting revealed that their AI-driven liquid biopsy platform achieved an area under the curve (AUC) exceeding 90% across roughly 1,000 real-world patient samples, signaling a major transition toward scalable, minimally invasive protocols capable of identifying cancer before metastasis.

Additionally, the surge in public and private funding for cancer research serves as a vital catalyst, supporting the continued development and market entry of these advanced diagnostic tools. Government agencies and philanthropic groups are increasingly directing funds toward high-risk, high-reward research centered on early detection and survivorship, which helps mitigate the risks associated with diagnostic R&D. According to a January 2025 press release, the Ovarian Cancer Research Alliance awarded over $9.2 million in grants during the previous year to foster advancements in detection and treatment. This financial support underscores the growing shift toward personalized medicine, a trend further illustrated by Roche's 2025 report of over 60 FDA-approved companion diagnostic tests currently available in oncology, highlighting the sector's reliance on precision medicine driven by biomarkers.

Market Challenges

A major obstacle hindering the expansion of the Global Ovarian Cancer Diagnostics Market is the lack of a sensitive and standardized screening method suitable for detecting the disease within the general population. In contrast to other oncology sectors that utilize established preventative screening protocols, ovarian cancer does not have a dependable, non-invasive test for women who are asymptomatic. This technological gap restricts market activity primarily to confirming diagnoses in patients presenting with symptoms, rather than enabling mass adoption for preventative purposes. As a result, the total addressable market is notably constrained, preventing manufacturers from tapping into the high-volume revenue potential inherent in routine, population-based screening programs.

This deficiency is directly linked to the high prevalence of late-stage diagnoses, which diminishes the perceived cost-effectiveness and clinical utility of current diagnostic instruments for early intervention. Data from the Ovarian Cancer Research Alliance indicates that in 2024, merely 16% of ovarian cancer cases were identified during the early stages. This low detection rate highlights the limitations of existing modalities, such as CA-125 testing and transvaginal ultrasound, in spotting early-onset malignancies. Consequently, insurers and healthcare payers remain reluctant to authorize widespread reimbursement for these diagnostics across the general public, further inhibiting commercial growth and market penetration.

Market Trends

Clinical decision-making regarding adnexal mass evaluation is being transformed by the shift from single-marker tests to index assays and multi-parametric biomarker panels. These Multivariate Index Assays (MIAs) employ proprietary algorithms to evaluate multiple proteins, including apolipoprotein A1 and transferrin alongside CA-125, providing enhanced specificity for assessing malignancy risk compared to standard immunoassays. This evolution meets the critical demand for precise pre-surgical triage, ensuring high-risk patients are correctly referred to gynecologic oncologists while minimizing unnecessary surgeries for benign cases. As reported by Aspira Women's Health in March 2025, the company saw a 9.5% year-over-year increase in product revenue for the fourth quarter of 2024, attributed to the growing uptake of its specialized gynecologic diagnostic offerings.

Concurrently, the integration of Next-Generation Sequencing (NGS) for extensive genetic profiling is pushing the standard of care beyond simple BRCA testing. Clinicians are increasingly utilizing Homologous Recombination Deficiency (HRD) status and genomic instability scores to guide the prescription of poly (ADP-ribose) polymerase (PARP) inhibitors. This requirement for comprehensive molecular characterization is fueling the adoption of high-throughput sequencing platforms that can detect both somatic and germline mutations within a single workflow, which is vital for personalized treatment plans. Highlighting this trend, Myriad Genetics announced in February 2025 that it achieved an 11% year-over-year revenue growth for the full year 2024, totaling $838 million, driven by strong volumes in its tumor profiling and hereditary cancer testing segments.

Key Players Profiled in the Ovarian Cancer Diagnostics Market

• F. Hoffmann-La Roche AG
• Johnson & Johnson Services, Inc.
• GlaxoSmithKline PLC
• AstraZeneca PLC
• Siemens Healthineers GmbH
• Abbott Laboratories
• Thermo Fisher Scientific
• Bio-Rad Laboratories, Inc.
• Quest Diagnostics Incorporated
• Illumina, Inc.

Report Scope

In this report, the Global Ovarian Cancer Diagnostics Market has been segmented into the following categories:

Ovarian Cancer Diagnostics Market, by Diagnosis Type:

• Diagnostic Imaging
• Blood Test
• Biopsy
• Others

Ovarian Cancer Diagnostics Market, by Cancer Type:

• Epithelial Tumor
• Germ Cell Tumor
• Stromal Cell Tumor
• Others

Ovarian Cancer Diagnostics Market, by End User:

• Hospitals & Specialty Clinics
• Ambulatory Care Centers
• Others

Ovarian Cancer Diagnostics Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ovarian Cancer Diagnostics Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.